PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2007; 28(03): 5-10
DOI: 10.1055/s-0041-1733221
Original Article

Survival Benefit and Efficacy of Gefitinib in Recurrent/ Metastatic Head and Neck Cancer

R. Ranga Rao
Department of Medical Oncology. Rajiv Gandhi Cancer Institute, Sector-5, Rohini, New Delhi-85, India
,
Anil Konnpal
Department of Medical Oncology. Rajiv Gandhi Cancer Institute, Sector-5, Rohini, New Delhi-85, India
,
Lalit Bansal
Department of Medical Oncology. Rajiv Gandhi Cancer Institute, Sector-5, Rohini, New Delhi-85, India
,
Amit Dhiman
Department of Medical Oncology. Rajiv Gandhi Cancer Institute, Sector-5, Rohini, New Delhi-85, India
,
Sameer Khatri
Department of Medical Oncology. Rajiv Gandhi Cancer Institute, Sector-5, Rohini, New Delhi-85, India
,
Shneh Rawat
Department of Medical Oncology. Rajiv Gandhi Cancer Institute, Sector-5, Rohini, New Delhi-85, India
,
Ajay Dewan
Department of Medical Oncology. Rajiv Gandhi Cancer Institute, Sector-5, Rohini, New Delhi-85, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
07. März 2022

© 2007. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 IARC. GLOBOCAN [Online]. 2002, [cited 2007 Aug 12]; Available from: URL: http://www-depdb.iarc.fr/ globocan.
  • 2 Grandis J, Tweardy D. Elevated levels of transforming growth factor á and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579–3584.
  • 3 Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980-1987.
  • 4 Wheeler RH, Jones D, Sharma R, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol. 2005;23:507s.Abstract 5531.
  • 5 Kirby AM, A’Hern RP, D’Ambrosio C, et al. Gefitinib (ZD1839, IressaTM) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006; 94(5):631-636.
  • 6 WHO (World Health Organization) Toxicity Criteria by Grade. [Online]. [cited 2007 Sept 8]; Available from: URL: http://www.accessdata.fda.gov/scripts/cder/ onctools/whotox.cfm
  • 7 Padhani A R, Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br. J. Radiol. 2001;74:983-986.
  • 8 Vermorken J, Bourhis J, Trigo J, et al. Cetuximab (Erbitux®) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. Proc Am Soc Clin Oncol. 2005;23:501s.Abstract 5505.
  • 9 Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell cancer: results from a randomized, placebo-controlled, multicentre study (IRESSA Survival Evaluation in Lung cancer), Lancet 2005;366: 1527-37.